JP2004501153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501153A5 JP2004501153A5 JP2002504258A JP2002504258A JP2004501153A5 JP 2004501153 A5 JP2004501153 A5 JP 2004501153A5 JP 2002504258 A JP2002504258 A JP 2002504258A JP 2002504258 A JP2002504258 A JP 2002504258A JP 2004501153 A5 JP2004501153 A5 JP 2004501153A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- chlorophenyl
- pharmaceutically acceptable
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XKBOADWPZLOLCO-UHFFFAOYSA-N (4-chlorophenyl)-[5-(3-chlorophenyl)tetrazolo[1,5-a]quinazolin-7-yl]-(3-methylimidazol-4-yl)methanamine Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(N3N=NN=C3N=C2C=2C=C(Cl)C=CC=2)=CC=1)C1=CC=C(Cl)C=C1 XKBOADWPZLOLCO-UHFFFAOYSA-N 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- -1 1-methyl-1H-imidazol-5-yl Chemical group 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 201000007249 familial juvenile hyperuricemic nephropathy Diseases 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00202181 | 2000-06-22 | ||
| EP00202181.4 | 2000-06-22 | ||
| PCT/EP2001/006747 WO2001098302A1 (en) | 2000-06-22 | 2001-06-13 | Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501153A JP2004501153A (ja) | 2004-01-15 |
| JP2004501153A5 true JP2004501153A5 (enExample) | 2008-07-17 |
| JP4919575B2 JP4919575B2 (ja) | 2012-04-18 |
Family
ID=8171675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002504258A Expired - Lifetime JP4919575B2 (ja) | 2000-06-22 | 2001-06-13 | ファルネシルトランスフェラーゼ阻害性１，２−環付加キノリン鏡像異性体 |
Country Status (33)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018135A1 (en) | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
| CA2481480C (en) | 2002-04-15 | 2011-04-12 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| US20050003422A1 (en) | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP2017536403A (ja) * | 2014-12-04 | 2017-12-07 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | デルタ肝炎ウイルス感染の治療 |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| HUE049620T2 (hu) | 2015-08-17 | 2020-09-28 | Kura Oncology Inc | Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal |
| PT3534885T (pt) | 2016-11-03 | 2021-04-13 | Kura Oncology Inc | Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1519765A (en) * | 1974-09-05 | 1978-08-02 | Ici Ltd | Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes |
| US4141979A (en) * | 1976-12-23 | 1979-02-27 | Pfizer Inc. | Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents |
| GB9513577D0 (en) * | 1995-07-04 | 1995-09-06 | Brotherwood Rodney J | Improvements in passenger carrying vehicles |
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| ATE321757T1 (de) * | 1995-12-08 | 2006-04-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| KR100520401B1 (ko) * | 1997-04-25 | 2005-10-12 | 얀센 파마슈티카 엔.브이. | 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논 |
| CA2290992C (en) | 1997-06-02 | 2008-02-12 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| HRP20000904A2 (en) | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| KR100591603B1 (ko) * | 1998-07-06 | 2006-06-20 | 얀센 파마슈티카 엔.브이. | 생체내 방사선 감작성을 갖는 파네실 단백질 트랜스퍼라제억제제 |
| EP1107962B1 (en) * | 1998-08-27 | 2005-02-23 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| JP3495706B2 (ja) * | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体 |
| US6458800B1 (en) * | 1998-12-23 | 2002-10-01 | Janssen Pharmaceutica N.V. | 1,2-annelated quinoline derivatives |
| US6462201B1 (en) * | 1998-12-29 | 2002-10-08 | Isp Investments Inc. | Process for the production of N-vinyl-2-pyrrolidone by vinylation |
| BR0008202A (pt) * | 1999-02-11 | 2002-02-19 | Pfizer Prod Inc | Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| EP1267848B1 (en) * | 2000-02-24 | 2007-10-17 | Janssen Pharmaceutica N.V. | Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer |
| US7067531B2 (en) | 2000-09-25 | 2006-06-27 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
| WO2002024686A2 (en) | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
-
2001
- 2001-05-29 JO JO200183A patent/JO2361B1/en active
- 2001-06-13 ES ES01938263T patent/ES2241830T3/es not_active Expired - Lifetime
- 2001-06-13 HU HU0300872A patent/HU229095B1/hu unknown
- 2001-06-13 NZ NZ522481A patent/NZ522481A/en not_active IP Right Cessation
- 2001-06-13 JP JP2002504258A patent/JP4919575B2/ja not_active Expired - Lifetime
- 2001-06-13 DE DE60110592T patent/DE60110592T2/de not_active Expired - Lifetime
- 2001-06-13 WO PCT/EP2001/006747 patent/WO2001098302A1/en not_active Ceased
- 2001-06-13 MX MXPA02012845A patent/MXPA02012845A/es active IP Right Grant
- 2001-06-13 BR BR0111743-2 patent/BRPI0111743B8/pt not_active IP Right Cessation
- 2001-06-13 EE EEP200200695A patent/EE04966B1/xx unknown
- 2001-06-13 CZ CZ2003114A patent/CZ295278B6/cs not_active IP Right Cessation
- 2001-06-13 AU AU6396201A patent/AU6396201A/xx active Pending
- 2001-06-13 CA CA002410232A patent/CA2410232C/en not_active Expired - Lifetime
- 2001-06-13 EA EA200300048A patent/EA005065B1/ru not_active IP Right Cessation
- 2001-06-13 KR KR1020077026608A patent/KR100846370B1/ko not_active Expired - Lifetime
- 2001-06-13 UA UA20021210152A patent/UA73572C2/uk unknown
- 2001-06-13 IL IL15356001A patent/IL153560A0/xx unknown
- 2001-06-13 EP EP01938263A patent/EP1296984B1/en not_active Expired - Lifetime
- 2001-06-13 US US10/312,301 patent/US20030114471A1/en not_active Abandoned
- 2001-06-13 AU AU2001263962A patent/AU2001263962B2/en not_active Expired
- 2001-06-13 AT AT01938263T patent/ATE294804T1/de active
- 2001-06-13 HR HR20020989A patent/HRP20020989B1/xx not_active IP Right Cessation
- 2001-06-13 SK SK50-2003A patent/SK285699B6/sk not_active IP Right Cessation
- 2001-06-13 KR KR1020027014678A patent/KR100831940B1/ko not_active Expired - Lifetime
- 2001-06-13 CN CNB018113788A patent/CN1207296C/zh not_active Expired - Lifetime
- 2001-06-13 PL PL358918A patent/PL209521B1/pl unknown
- 2001-06-14 PA PA20018519501A patent/PA8519501A1/es unknown
- 2001-06-20 MY MYPI20012896A patent/MY127734A/en unknown
- 2001-06-20 EG EG20010660A patent/EG24180A/xx active
- 2001-06-21 AR ARP010102954A patent/AR030704A1/es not_active Application Discontinuation
- 2001-09-10 SA SA01220349A patent/SA01220349B1/ar unknown
-
2002
- 2002-10-25 IS IS6590A patent/IS2596B/is unknown
- 2002-11-25 BG BG107310A patent/BG65894B1/bg unknown
- 2002-12-16 NO NO20026032A patent/NO324494B1/no not_active IP Right Cessation
- 2002-12-19 IL IL153560A patent/IL153560A/en not_active IP Right Cessation
- 2002-12-19 ZA ZA200210305A patent/ZA200210305B/en unknown
-
2006
- 2006-09-20 AU AU2006220405A patent/AU2006220405B2/en not_active Expired
-
2007
- 2007-01-31 US US11/669,587 patent/US8329714B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/926,741 patent/US8318753B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3284467B1 (en) | Nicotine-containing pharmaceutical compositions | |
| RU2001134300A (ru) | Фармацевтические и пищевые композиции, содержащие незаменимые жирные кислоты и гомоцистеин-понижающие агенты | |
| JP2005537268A5 (enExample) | ||
| JPS62215527A (ja) | アルツハイマー病治療薬 | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2005515966A5 (enExample) | ||
| JPS5925323A (ja) | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 | |
| JP2005510535A5 (enExample) | ||
| PT1311272E (pt) | Novos métodos utilizando inibidores de colinesterase | |
| JP2004501153A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| JP2019528302A5 (enExample) | ||
| WO2013002365A1 (ja) | 止痒剤 | |
| TW202140022A (zh) | 以ｐｒｍｔ５抑制劑治療乾癬及其他自體免疫性病況之方法 | |
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| AU2003227304B2 (en) | Pharmaceutical formulation comprising melatonin | |
| US20100292280A1 (en) | Anti-pyretic vasodilators | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| TWI411435B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於治療脊髓創傷之用途 | |
| JP2002515439A5 (enExample) | ||
| JP2002537232A5 (enExample) | ||
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| JP2005513105A5 (enExample) | ||
| KR20210137484A (ko) | 캡시드 조립 조절제 고체 제형 | |
| CN102552210B (zh) | 一种恩替卡韦胶囊组合物及其制备方法 |